TY - JOUR
T1 - A community effort to create standards for evaluating tumor subclonal reconstruction
AU - DREAM SMC-Het Participants
AU - Salcedo, Adriana
AU - Tarabichi, Maxime
AU - Espiritu, Shadrielle Melijah G.
AU - Deshwar, Amit G.
AU - David, Matei
AU - Wilson, Nathan M.
AU - Dentro, Stefan
AU - Wintersinger, Jeff A.
AU - Liu, Lydia Y.
AU - Ko, Minjeong
AU - Sivanandan, Srinivasan
AU - Zhang, Hongjiu
AU - Zhu, Kaiyi
AU - Ou Yang, Tai Hsien
AU - Chilton, John M.
AU - Buchanan, Alex
AU - Lalansingh, Christopher M.
AU - P’ng, Christine
AU - Anghel, Catalina V.
AU - Umar, Imaad
AU - Lo, Bryan
AU - Zou, William
AU - Jha, Alokkumar
AU - Huang, Tanxiao
AU - Yang, Tsun Po
AU - Peifer, Martin
AU - Sahinalp, Cenk
AU - Malikic, Salem
AU - Vázquez-García, Ignacio
AU - Mustonen, Ville
AU - Yang, Hsih Te
AU - Lee, Ken Ray
AU - Ji, Yuan
AU - Sengupta, Subhajit
AU - Rudewicz, Justine
AU - Nikolski, Macha
AU - Schaeverbeke, Quentin
AU - Yuan, Ke
AU - Markowetz, Florian
AU - Macintyre, Geoff
AU - Cmero, Marek
AU - Chaudhary, Belal
AU - Leshchiner, Ignaty
AU - Livitz, Dimitri
AU - Getz, Gad
AU - Loher, Phillipe
AU - Yu, Kaixian
AU - Wang, Wenyi
AU - Zhu, Hongtu
AU - Simpson, Jared T.
N1 - Funding Information:
We thank the members of their laboratories for support, and Sage Bionetworks and the DREAM Challenge organization for their ongoing support of the SMC-Het Challenge. In particular, we thank T. Norman, J.C. Bare, S. Friend and G. Stolovitzky for their patience, technical support and scientific insight. We also thank R. Sun and C. Curtis for kindly sharing code for calculating the intra-tumor heterogeneity metrics and building the support vector machine predictor in multi-region sequencing simulations. This study was conducted with the support of the Ontario Institute for Cancer Research to P.C.B. and J.T.S. through funding provided by the Government of Ontario. This work was supported by Prostate Cancer Canada and is proudly funded by the Movember Foundation (Grant no. RS2014-01 to P.C.B.). This study was conducted with the support of Movember funds through Prostate Cancer Canada and with the additional support of the Ontario Institute for Cancer Research, funded by the Government of Ontario. This project was supported by Genome Canada through a Large-Scale Applied Project contract to P.C.B., S.P. Shah and R.D. Morin. This work was supported by the Discovery Frontiers: Advancing Big Data Science in Genomics Research program, which is jointly funded by the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health Research (CIHR), Genome Canada and the Canada Foundation for Innovation (CFI). Q.M. is a Canada CIFAR AI chair and is supported by an Associate Investigator award from OICR. This research is part of the University of Toronto’s Medicine by Design initiative, which receives funding from the Canada First Research Excellence Fund (CFREF). J.A.W. was partially supported by an Ontario Graduate Scholarship. This work was supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (grant no. FC001202), the UK Medical Research Council (grant no. FC001202), and the Wellcome Trust (grant no. FC001202). M.T. is a postdoctoral fellow supported by the European Union’s Horizon 2020 research and innovation program (Marie Sklodowska-Curie Grant Agreement no. 747852-SIOMICS). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation’s support toward the establishment of The Francis Crick Institute. This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the UK Medical Research Council (grant no. MR/L016311/1 to M.T. and P.V.L.). A.S. was partly supported by a CIHR CGS-doctoral award. P.C.B. was supported by a Terry Fox Research Institute New Investigator Award and a CIHR New Investigator Award. D.C.W. is supported by the Li Ka Shing foundation. The Galaxy portions of the evaluation system were supported by National Institutes of Health (NIH) grant nos. U41 HG006620 and R01 AI134384-01 as well as NSF grant no. 1661497. The following NIH grants supported this work: no. R01-CA180778 (to J.M.S.), no. U24-CA143858 (to J.M.S.) and no. P30-CA008748 (to Thompson, subgrant to Q.M.). We thank Google Inc. (in particular N. Deflaux) for their ongoing support of the ICGC-TCGA DREAM Somatic Mutation Calling Challenge. This work was supported by the NIH/NCI under award no. P30CA016042.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Tumor DNA sequencing data can be interpreted by computational methods that analyze genomic heterogeneity to infer evolutionary dynamics. A growing number of studies have used these approaches to link cancer evolution with clinical progression and response to therapy. Although the inference of tumor phylogenies is rapidly becoming standard practice in cancer genome analyses, standards for evaluating them are lacking. To address this need, we systematically assess methods for reconstructing tumor subclonality. First, we elucidate the main algorithmic problems in subclonal reconstruction and develop quantitative metrics for evaluating them. Then we simulate realistic tumor genomes that harbor all known clonal and subclonal mutation types and processes. Finally, we benchmark 580 tumor reconstructions, varying tumor read depth, tumor type and somatic variant detection. Our analysis provides a baseline for the establishment of gold-standard methods to analyze tumor heterogeneity.
AB - Tumor DNA sequencing data can be interpreted by computational methods that analyze genomic heterogeneity to infer evolutionary dynamics. A growing number of studies have used these approaches to link cancer evolution with clinical progression and response to therapy. Although the inference of tumor phylogenies is rapidly becoming standard practice in cancer genome analyses, standards for evaluating them are lacking. To address this need, we systematically assess methods for reconstructing tumor subclonality. First, we elucidate the main algorithmic problems in subclonal reconstruction and develop quantitative metrics for evaluating them. Then we simulate realistic tumor genomes that harbor all known clonal and subclonal mutation types and processes. Finally, we benchmark 580 tumor reconstructions, varying tumor read depth, tumor type and somatic variant detection. Our analysis provides a baseline for the establishment of gold-standard methods to analyze tumor heterogeneity.
UR - http://www.scopus.com/inward/record.url?scp=85077732092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077732092&partnerID=8YFLogxK
U2 - 10.1038/s41587-019-0364-z
DO - 10.1038/s41587-019-0364-z
M3 - Article
C2 - 31919445
AN - SCOPUS:85077732092
SN - 1087-0156
VL - 38
SP - 97
EP - 107
JO - Nature Biotechnology
JF - Nature Biotechnology
IS - 1
ER -